Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys TNDM Stock

Democratic Representative Gilbert Ray Cisneros Jr. picked up shares of medical device maker Tandem Diabetes Care, Inc. (NasdaqGM: TNDM) in a late-September trade, according to a periodic transaction report filed under the STOCK Act. The transaction, executed on September 29, 2026, was valued between $1,001 and $15,000. Under congressional disclosure rules, the trade was later made public on October 12, 2026.

Inside Rep. Gilbert Ray Cisneros Jr.'s Tandem Diabetes Care Trade

The House filing reveals that the Democratic lawmaker added to his personal portfolio with the purchase of TNDM shares. Because congressional disclosures provide ranges rather than exact dollar figures or share amounts, the exact size of the stake remains unknown beyond the $1,001 to $15,000 bracket. On the day of the trade, Tandem Diabetes Care closed at $16.57 on the NasdaqGM.

Other Institutional Activity in Tandem Diabetes Care

Large investment firms have been adjusting their own positions in the medical device maker during recent reporting periods. Blackrock Inc. grew its holdings by 892,654 shares, ending with 11,583,125 shares worth about $188,109,947. Sessa Capital IM, L.P. added 369,456 shares for a total of 5,100,000 shares valued at about $82,823,998. Vanguard Portfolio Management LLC increased its stake by 306,292 shares to finish with 4,299,667 shares worth roughly $69,826,591. First Light Asset Management, LLC boosted its holdings by 2,068,837 shares, owning 3,383,553 shares valued at about $54,948,899. Vanguard Capital Management LLC grew its position by 57,737 shares to hold 3,096,536 shares worth roughly $50,287,743.

Tandem Diabetes Care, Inc. Stock Down 1.7%

Tandem Diabetes Care shares recently traded around $16.76 as of October 16, 2026, putting the stock up about 1.1% since the September trade date. The stock has a 52-week high of $29.65 and a 52-week low of $12.26.

Recent Earnings

For its trailing twelve months, the company reported revenue of $1,041,417,024 and earnings per share of -$0.91, alongside a year-over-year revenue growth rate of 5.8%. The company is scheduled to report its next set of financial results on November 5, 2026.

Insider Buying and Selling at Tandem Diabetes Care, Inc.

Corporate insiders have not reported open-market transactions in recent data filings for the company.

Analysts Set New Price Targets

Wall Street firms have active coverage on the stock. On July 15, 2026, Mizuho maintained its Neutral rating with a target price of $20.00. Later, on August 7, 2026, Citigroup kept its Neutral rating while adjusting its target to $21.00, and RBC Capital maintained an Outperform rating with a $26.00 target. On August 21, 2026, William Blair initiated coverage with an Outperform rating. Most recently, on September 24, 2026, Truist Securities maintained a Buy rating with a target price of $28.00. Across the broader analyst community, the stock carries a consensus buy rating with a mean target price of $27.76 based on 21 analyst opinions.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs and manufactures automated insulin delivery systems and medical technology for patients managing diabetes. Its flagship offerings include the t:slim X2 insulin delivery system and the Tandem Mobi pump, alongside single-use cartridges and infusion sets. The San Diego-based company operates within the healthcare sector.

Bottom Line

Market participants tracking congressional trading activity can monitor upcoming disclosures from Representative Cisneros for any further adjustments to his portfolio. The company's next earnings report on November 5, 2026, will provide updated operational figures for the business.